Morgan Stanley analyst Tejas Savant maintained a Buy rating on 10x Genomics (TXG – Research Report) today and set a price target of $26.00. The company’s shares closed yesterday at $11.94.

Shares of biotech company 10x Genomics (NASDAQ:TXG) fell 8.5% in the pre-market session after the company reported disappointing fourth-quarter results: its EPS missed significantly, and its full ...

Biotech company 10x Genomics (NASDAQ:TXG) will be reporting earnings tomorrow after market hours. Here’s what to look for. 10x Genomics missed analysts’ revenue expectations by 5% last quarter ...

In trading on Monday, shares of 10x Genomics Inc (Symbol: TXG) entered into oversold territory, hitting an RSI reading of 27.9, after changing hands as low as $11.8955 per share. By comparison ...

NASDAQ TXG opened at $12.31 on Thursday. The stock’s 50 day moving average is $14.68 and its 200 day moving average is $17.35. The stock has a market cap of $1.49 billion, a PE ratio of -8.05 ...

TXG opened at $12.31 on Thursday. The stock has a market cap of $1.49 billion, a price-to-earnings ratio of -8.05 and a beta of 1.85. 10x Genomics has a 1 year low of $10.80 and a 1 year high of ...

Thank you for standing by. My name is [Prilla] and I will be your conference operator today. At this time, I would like to welcome everyone to the 10x Genomics Fourth Quarter and Full Year 2024 ...

In a report released today, Michael Ryskin from Bank of America Securities maintained a Hold rating on 10x Genomics (TXG – Research Report). The company’s shares opened today at $14.74.

In this article, we are going to take a look at where 10x Genomics, Inc. (NASDAQ:TXG) stands against the other stocks in Cathie Wood’s portfolio. Cathie Wood is one of Wall Street’s most ...